Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1) - Papp, Kim; Reich, Kristian; Leonardi, Craig L.; Kircik, Leon; Chimenti, Sergio; Langley, Richard G.B.; Hu, ChiaChi; Stevens, Randall M.; Day, Robert M.; Gordon, Kenneth B.; Korman, Neil J.; Griffiths, Christopher E.M. (Journal of the American Academy of Dermatology, 2015)
Keywords: Administration, Oral; apremilast; clinical trial; Dermatology; Double-Blind Method; ESTEEM; Female; Humans; Male; Middle Aged; phosphodiesterase 4 inhibitor; Phosphodiesterase 4 Inhibitors - administration & dosage; psoriasis; Psoriasis - drug therapy; Severity of Illness Index; Thalidomide - administration & dosage; Thalidomide - analogs & derivatives; treatment; clinical trial; treatment; FDA; PASI; sPGA; IL; AE; PDE4; apremilast; ESTEEM; Th; PASI-75; psoriasis; SAE; phosphodiesterase 4 inhibitor; static Physician Global Assessment; Psoriasis Area and Severity Index; phosphodiesterase 4; serious adverse event; interleukin; Food and Drug Administration; T helper; Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; adverse event; 75% or greater reduction from baseline Psoriasis Area and Severity Index score